Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

This study has suspended participant recruitment.
(Drug supply issues)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT02079740
First received: March 4, 2014
Last updated: October 5, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)